Targeted therapeutic options in early and metastatic NSCLC-overview

Targeted therapeutic options in early and metastatic NSCLC-overview

The complex therapeutic strategy of non-small cell lung cancer (NSCLC) has changed significantly in recent years. Disease-free survival increased significantly with immunotherapy and chemotherapy registered in perioperative treatments, as well as adjuvant registered immunotherapy and targeted therap...

Full description

Bibliographic Details
Main Authors:	Gabriella Gálffy, Éva Morócz, Réka Korompay, Réka Hécz, Réka Bujdosó, Rita Puskás, Tímea Lovas, Eszter Gáspár, Kamel Yahya, Péter Király, Zoltán Lohinai
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-03-01
Series:	Pathology and Oncology Research
Subjects:	NSCLC driver oncogenes targeted therapy central nervous system efficacy molecular testing
Online Access:	https://www.por-journal.com/articles/10.3389/pore.2024.1611715/full

Similar Items

Oligometastatic NSCLC: Current Perspectives and Future Challenges
by: Sara Torresan, et al.
Published: (2025-01-01)

Capmatinib-induced interstitial lung disease: A case report
by: Kinan El Husseini, et al.
Published: (2020-12-01)

Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC
by: Umberto Malapelle, et al.
Published: (2023-06-01)

Co-Occurrence of ALK rearrangement and KRAS G12C mutation in NSCLC: Report of two cases
by: M Siringo, et al.
Published: (2024-06-01)

The rapidly changing field of predictive biomarkers of non-small cell lung cancer
by: László József Tóth, et al.
Published: (2024-06-01)

Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy
by: Fei-fei Gu, et al.
Published: (2016-08-01)

Rare Driver Mutations in Advanced, Oncogene-Addicted Non-Small Cell Lung Cancer: A North Italian, Real-World, Registry Experience
by: Kalliopi Andrikou, et al.
Published: (2024-05-01)

Activating mutations in EGFR and PI3K promote ATF4 induction for NSCLC cell survival during amino acid deprivation
by: Mizuki Takahashi, et al.
Published: (2023-04-01)

Efficacy of first‐line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations
by: Yuji Uehara, et al.
Published: (2022-06-01)

The oncogenic role and regulatory mechanism of PGK1 in human non-small cell lung cancer
by: Tian Tian, et al.
Published: (2024-01-01)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
by: Yijia Du, et al.
Published: (2022-12-01)

The Value of Radiotherapy for Advanced Non-Small Cell Lung Cancer With Oncogene Driver-Mutation
by: Jinfeng Cui, et al.
Published: (2022-05-01)

Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report
by: Alessandro Inno, et al.
Published: (2023-06-01)

Exploiting signaling rewiring in cancer cells with co‐existing oncogenic drivers
by: Roberto Chiarle, et al.
Published: (2023-11-01)

Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC
by: Weijie Ma, et al.
Published: (2021-09-01)

Neuroblastoma—A Neural Crest Derived Embryonal Malignancy
by: John Inge Johnsen, et al.
Published: (2019-01-01)

Diagnostics for Targeted NSCLC Therapy
by: Verena Schildgen, et al.
Published: (2017-11-01)

Diagnostic and Therapeutic Strategy Updates of Rare Oncogenic Mutations in Chinese Society of Clinical Oncology Guidelines on Diagnosis and Treatment of Non-small Cell Lung Cancer (2023 Edition)
by: LI Yingge, et al.
Published: (2023-12-01)

A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature
by: Shannon S. Zhang, MD, et al.
Published: (2022-09-01)

The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study
by: David J. Benjamin, MD, et al.
Published: (2022-12-01)

ATM inhibition blocks glucose metabolism and amplifies the sensitivity of resistant lung cancer cell lines to oncogene driver inhibitors
by: Cristina Terlizzi, et al.
Published: (2023-11-01)

Driving Examiners’ Perceptions and Awareness of Advanced Driver Assistance Systems: A Survey-Based Analysis
by: Boglárka Eisinger Balassa, et al.
Published: (2024-11-01)

Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC
by: Ceva Wicaksono Pitoyo, et al.
Published: (2022-04-01)

Oncogenic mutant KRAS inhibition through oxidation at cysteine 118
by: Maximilian Kramer‐Drauberg, et al.
Published: (2025-02-01)

CaDrA: A Computational Framework for Performing Candidate Driver Analyses Using Genomic Features
by: Vinay K. Kartha, et al.
Published: (2019-02-01)

To Become or Not to Become Tumorigenic: Subventricular Zone Versus Hippocampal Neural Stem Cells
by: Ángela Fontán-Lozano, et al.
Published: (2020-11-01)

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults
by: D. Gwyn Bebb, et al.
Published: (2021-01-01)

Gut resistome of NSCLC patients treated with immunotherapy
by: Ewelina Iwan, et al.
Published: (2024-08-01)

Forkhead Box O (FOXO) signaling in NSCLC
by: Lakshmi Thangavelu, et al.
Published: (2024-05-01)

Impact of NSCLC metabolic remodeling on immunotherapy effectiveness
by: Lulu Lv, et al.
Published: (2022-08-01)

Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations
by: Huijuan Wang, et al.
Published: (2020-01-01)

Research progress in drug therapy for NSCLC with rare driver gene mutation
by: LIU Ying, et al.
Published: (2023-06-01)

Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status
by: David Dora, et al.
Published: (2023-12-01)

Focus on Nintedanib in NSCLC and other tumors
by: Anna Manzo, et al.
Published: (2016-12-01)

The Landscape of Immunotherapy Resistance in NSCLC
by: Daniele Frisone, et al.
Published: (2022-04-01)

Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study
by: Lauren Julia Brown, M.B.B.S., MClinTRes, FRACP, et al.
Published: (2024-10-01)

Editorial: The Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) in a New Era of Personalised Medicine
by: Vera eHirsh
Published: (2015-02-01)

The role of chemoradiotherapy and immunotherapy in stage III NSCLC
by: Zsuzsanna Orosz, et al.
Published: (2024-04-01)

First-Line Treatment of ALK-Positive NSCLC
by: Hasna Bouchaab
Published: (2019-11-01)

Mutational Profiling by Next-Generation Sequencing in Patients with Metastatic Non-Small Cell Lung Carcinoma: Our Experience
by: Hitesh Deka, et al.